Ipsen has become an active dealmaker as it pursues growth in oncology, and its latest move is the $450 million acquisition of Kartos Therapeutics, a clinical-stage biotech whose lead program could ...
A metabolic disorder that leads to high levels of fat in the blood and life-threatening pancreatic complications now has its first FDA-approved medicine, an RNA-targeting therapy developed by Ionis ...
Wearable devices have surged over the past decade, from fitness trackers to smartwatches to smart rings. Yet their development has often been shaped around the most easily measured parts of health: ...
One of the most challenging aspects of treating many diseases, including cancer and inflammatory conditions, is that they are highly heterogeneous. In patients with the same diagnosis, both clinical ...
Health systems today are pursuing an “all of the above” strategy when it comes to finding inpatient capacity. That means both working every lever to keep patients out of the hospital, and then moving ...
Cadence raised $100 million in Series C funding to scale its AI-powered chronic care platform, which monitors patients at ...
Ladder Health, a virtual-first pediatric developmental care startup, announced on Tuesday that it secured $7 million in seed funding to expand into new markets. Boston-based Ladder Health supports ...
New federal attention to psychedelic research and a major Texas-funded clinical trial initiative are moving compounds like ibogaine from the margins of substance use disorder (SUD) treatment debate ...
As a Sanofi veteran, Frédéric Marrache is well aware of the innovations shaping immunology. His tenure there came as Dupixent grew into the company’s top-selling product, now spanning nine ...
The case that many startups are making for automating the healthcare revenue cycle is pretty straightforward. Claims follow rules, payers adhere to guidelines, and most of this work is repetitive ...
UniQure is preparing to seek accelerated FDA approval for its Huntington’s disease gene therapy, a move that follows the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results